Phase III Melanoma Trial Design For Vical’s Allovectin-7 Expected By Year-End
This article was originally published in The Pink Sheet Daily
Executive Summary
However, an FDA warning letter to a clinical investigator in a Phase II high-dose trial of the gene therapy could complicate the company’s efforts to reach an agreement with the agency on trial design. The agency cited an Illinois researcher for protocol violations.